Indicam

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Indicam

Quick Facts: Indicam Overview

Property Description
Active Ingredient Diclofenac
Form Versatile (e.g., Oral tablets, topical gels, injectable solutions)
Pharmacological Class Nonsteroidal Anti-inflammatory Drug (NSAID)
General Purpose Provides anti-inflammatory, analgesic, and antipyretic effects
Origin Synthetic (Phenylacetic acid derivative)

What Type of Medicine is Indicam and Its Core Active Ingredient?

Indicam is a pharmaceutical preparation whose primary active ingredient is Diclofenac, a substance belonging to the Nonsteroidal Anti-inflammatory Drug (NSAID) class. This places Indicam within the category of medicines that work by targeting inflammation, pain, and fever in the body. Diclofenac is a synthetic compound derived from phenylacetic acid.

As a single-ingredient product, Indicam's fundamental purpose is centered on the inherent properties of Diclofenac. The drug is characterized by its potent anti-inflammatory action and is often utilized when addressing symptoms arising from inflammatory joint conditions. The official classification as an NSAID reflects its primary pharmacological class and mechanism of action.


Composition, Origin, and Available Forms

Indicam is manufactured and distributed in a versatile range of dosage forms—including oral tablets, topical gels or patches, and solutions for injection—to achieve therapeutic effects either throughout the body or locally.

The formulation contains Diclofenac as the active substance alongside various non-active excipients that determine the final form. This versatility means the medicine can be delivered via different routes of administration, including oral, topical, rectal, or parenteral. Diclofenac acts by inhibiting cyclooxygenase enzymes, which reduces the production of prostaglandins, thereby mitigating inflammation. This foundational mechanism shows the drug's core benefit is tied directly to managing the biological signals that cause pain and swelling.


General Purpose: The Anti-Inflammatory, Analgesic, and Antipyretic Effect

The general purpose of Indicam is to reduce the body’s inflammatory responses, thereby providing relief from associated pain, swelling, and fever. This integrated three-pronged action (anti-inflammatory, analgesic, and antipyretic) is the defining therapeutic benefit of the medicine. Collectively, these properties ensure the medicine is generally useful for managing symptoms that arise from various inflammatory states, such as the aches associated with muscle strains or common acute discomforts.

What side effects are possible with Indicam?

Indicam (a Non-Steroidal Anti-Inflammatory Drug, or NSAID) is associated with a defined safety profile that includes both common and serious adverse reactions, as documented in regulatory labeling.

Serious and Clinically Significant Adverse Reactions

Regulatory documents emphasize two primary warnings for systemic NSAIDs. The first is an increased risk of serious Cardiovascular Thrombotic Events such as heart attack (myocardial infarction) and stroke, which can be fatal. This risk may be heightened with longer duration of use and in individuals with pre-existing cardiovascular disease. The second significant risk is serious Gastrointestinal (GI) Adverse Events, including bleeding, ulceration, and perforation of the stomach or intestines, which can occur without warning symptoms and may be fatal.

Additional serious or clinically significant reactions include new onset or worsening hypertension, fluid retention and edema (which can worsen heart failure), potential kidney (renal) injury (including acute kidney failure), and serious skin reactions (such as Stevens-Johnson syndrome).

Common Adverse Reactions

Adverse reactions reported with higher frequency (Common, ge 1/100 to < 1/10) are generally related to the Central Nervous System (CNS) and GI System:

  • Gastrointestinal: Nausea, vomiting, indigestion, heartburn, stomach pain, diarrhea, and constipation.
  • Nervous System: Headache and dizziness are commonly reported.

Population-Specific Safety Considerations

Use of Indicam is not recommended after 20 weeks gestation, as NSAIDs can cause fetal kidney problems and other complications. Patients who are elderly, have a history of GI bleeding or ulcers, or have cardiovascular risk factors are generally at increased risk for the most serious adverse events. Due to potential effects on the kidneys and CNS, caution and dose adjustments may be warranted for geriatric patients.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes a Diclofenac overdose as a serious event with multi-system manifestations, necessitating immediate action. Treatment for an Indicam overdose is primarily symptomatic and supportive, as no specific antidote is known.

Documented Overdose Manifestations

System Regulator-Listed Signs and Symptoms
Gastrointestinal Nausea, vomiting, abdominal pain, diarrhea, and potentially severe bleeding
Central Nervous System Dizziness, drowsiness, confusion, headache, blurred vision, tinnitus, seizures, or coma in severe cases
Renal/Cardiovascular Acute renal failure, high or low blood pressure, increased heart rate, and edema

Mandatory Emergency Actions

Regulatory authorities mandate that any suspected overdose requires immediate emergency medical attention. Users must contact emergency services or a Poison Control center right away, regardless of initial symptom severity. A large overdose is explicitly documented as potentially life-threatening to both adults and children.

Supportive measures officially described include continuous monitoring of vital signs, specific blood and urine tests, and procedures such as activated charcoal, intravenous fluid support, or potentially endoscopy to manage internal bleeding.

Specific overdose risk factors noted in labeling include increased vulnerability to renal toxicity in patients with pre-existing kidney or liver impairment, and a higher risk of serious gastrointestinal events in elderly patients.

Therapeutic Uses of Indicam

What Indicam Treats: Main Uses and Benefits

This medication is commonly used across domains where additional symptomatic support is needed to address discomfort and inflammation, relevant in conditions involving episodic or fluctuating manifestations. It is generally considered relevant for easing symptoms related to physical discomfort, swelling, and stiffness.

This medicine is applied across therapeutic domains where short-term symptom management is appropriate, such as in conditions characterized by periods of heightened symptoms or recurrent episodes. It helps address symptom clusters that may become intense or disruptive and contributes to improved comfort during symptomatic periods.

Quick Fact: Supports Symptomatic Management of Pain and Stiffness

How This Supports Your Daily Comfort

The medication may assist with easing the overall symptom burden. It is used in clinical settings that involve acute or unstable symptom patterns, offering supportive relief when symptoms intensify and assisting with maintaining functional stability. This support may help patients cope more steadily with symptom fluctuations.

Regulatory References

  1. NIH MedlinePlus overview of Meloxicam

Eligibility and Restrictions for Use

Indicam (Diclofenac) eligibility is strictly defined by regulatory authorities based on a patient’s health history, particularly concerning NSAID-related risks. Use is primarily established for adult patients (18 years and older).


Absolute Contraindications (Must Not Use)

Condition/Population Status
Aspirin-Sensitive Asthma or NSAID Allergy Contraindicated
Severe Heart Failure (NYHA Class II-IV) Contraindicated
Post-CABG Surgery Pain Treatment Contraindicated
Active GI Ulcer/Bleeding or Perforation Contraindicated
Severe Hepatic or Renal Failure Contraindicated
Third Trimester of Pregnancy (ge 30 weeks) Contraindicated

Populations Requiring Restricted Use

Use is restricted and requires careful consideration and close monitoring for several groups. Geriatric patients (65+) should be treated with caution due to increased vulnerability. Use in the second trimester of pregnancy (20 to 29 weeks) must be limited to the lowest dose for the shortest duration. Patients with significant cardiovascular risk factors (e.g., hypertension, diabetes) or a history of GI disease require explicit medical assessment and supervision before use.

What should I know about interactions with other medicines?

Indicam (meloxicam) can interact with a range of other medications, potentially increasing the risk of side effects or altering the effectiveness of either drug. It is essential to inform your healthcare provider about all prescription, over-the-counter (OTC) medicines, and supplements you are currently taking.

Increased Risk of Bleeding and Ulcers

Co-administering Indicam with the following medicines significantly increases the risk of serious gastrointestinal bleeding and ulceration:

  • Other Nonsteroidal Anti-inflammatory Drugs (NSAIDs): Including aspirin (used for pain or blood-thinning), ibuprofen, or naproxen.
  • Anticoagulants and Antiplatelet Agents: Such as warfarin, clopidogrel, or apixaban.
  • Corticosteroids: Such as prednisone or dexamethasone.
  • Certain Antidepressants: Specifically Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs).

Potential for Reduced Effectiveness or Toxicity

The following interactions can either reduce the effectiveness of the listed medicine or increase the concentration and toxicity of Indicam or the interacting drug:

Interacting Drug Class Potential Effect
Diuretics and Blood Pressure Medicines (e.g., ACE inhibitors, ARBs, Beta-blockers) Reduced blood pressure-lowering effect; increased risk of kidney impairment.
Lithium (for bipolar disorder) Increased lithium levels, potentially leading to toxicity.
Methotrexate (for arthritis or cancer) Increased methotrexate levels, raising the risk of toxicity.
Cyclosporine (immunosuppressant) Increased risk of kidney toxicity.

Alcohol consumption while taking Indicam should be avoided as it significantly elevates the risk of stomach bleeding and ulcers. Always discuss your complete medical history and medication list with your doctor or pharmacist to manage potential interactions safely.

Mechanism of Action

Enzyme-Mediated Modulation of Inflammatory Mediators

The mechanism of action of Diclofenac involves the modulation of two primary systems: the chemical synthesis of inflammatory mediators and the electrical transmission of nociceptive signals.

This core mechanism involves the inhibition of Cyclooxygenase (COX) enzymes, particularly the inducible COX-2 enzyme, which is activated during tissue injury. By blocking COX-2 activity, the molecule restricts the enzymatic synthesis of inflammatory mediators like prostaglandin E2 ( PGE2), thereby limiting the chemical signals that sensitize nerve endings and elevate the body's thermoregulatory set point. This molecular action leads directly to the anti-inflammatory and antipyretic physiological effects.

Direct Attenuation of Nociceptive Neural Signaling

The second key domain involves a non-COX mechanism: the direct blockade of specific ion channels (such as Na^+ and ASICs) on peripheral sensory neurons. This interaction stabilizes the nerve cell membrane, which limits the electrical impulses necessary for signal propagation along the sensory nerve. This direct interference with the speed and flow of nociceptive signaling results in the modulation of the analgesic physiological response, independent of the reduction in chemical inflammation.

Dosage and Administration Information

How to Use Indicam: Official Administration Guidelines

This section outlines the approved instructions for the administration of Indicam (Diclofenac Sodium) as specified in official regulatory documents. Adherence to these strict protocols is mandatory for all administration.


Administration Scope

Feature Official Instruction Summary
Route of Administration Primarily Oral (e.g., delayed-release tablets, extended-release tablets, oral solution powder) and Topical (e.g., gel, solution) formulations are available. Intramuscular and Intravenous routes exist for acute management in controlled settings.
Dosing Schedule The adult oral dose for chronic conditions typically ranges from 100 mg to 150 mg daily, divided into two or three doses. Extended-release forms are usually administered once daily (e.g., 100 mg).
Timing and Preparation Oral Powder for Solution must be mixed only with a specified small volume of water (e.g., 30–60 mL) and consumed immediately. Certain oral forms, such as those for acute migraine, are most effective when taken on an empty stomach.
Handling Restrictions Delayed-release and extended-release tablets must be swallowed whole; they are not to be crushed, chewed, or split as this compromises the intended drug release mechanism.

Procedural Directives

The most critical procedural constraint governing the use of Indicam, applicable to all forms, is the mandate to utilize the lowest effective dosage for the shortest duration consistent with individual treatment goals.

Age-Group Rules: The lowest effective dose should be selected for elderly patients and those with low body weight, who may be more susceptible to systemic exposure and subsequent risks.

Missed Doses: If a dose is missed, guidance advises taking it as soon as it is remembered unless it is nearly time for the next scheduled dose, in which case the missed dose should be skipped; doses should not be doubled.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Indicam

This overview describes the types of clinical research conducted for the medicine Indicam (Diclofenac) and summarizes what has been observed in those studies, based on information reviewed by governmental and scientific bodies. This section focuses only on the research record and does not contain treatment instructions or medical advice.


Evidence for Symptom Management in Chronic Joint Conditions

Indicam was studied for research exploring symptom patterns related to Osteoarthritis (OA) and Rheumatoid Arthritis (RA), which are conditions marked by functional limitations and cycles of stability and flare-ups. For OA, the evidence primarily includes Randomized Controlled Trials (RCTs) and comprehensive Meta-analyses. These studies focused on outcomes related to physical discomfort and daily functioning, often measuring changes in joint pain, stiffness, and overall mobility scores.

Research exploring short-term symptom changes reported measurements of changes in function and pain scales over periods typically lasting from a few weeks up to three months. Studies comparing the oral tablet form and the topical gel form in OA often described patterns where both formulations were associated with changes measured during the study period. For Rheumatoid Arthritis (RA), studies monitored patient-reported outcomes describing perceived discomfort, exploring outcomes related to inflammatory states, and tracked changes in tender and swollen joint counts.


Evidence for Relief in Acute Pain and Injury

Indicam was evaluated in research exploring how symptoms change over time for acute, short-term pain, such as pain following soft-tissue injuries (like sprains) and pain after procedures (such as dental surgery). The research base for acute pain is dominated by Randomized Controlled Trials (RCTs) designed to measure acute symptom patterns. These trials examined outcomes describing episodic or acute changes, including the time it took for patients to experience a change in measured pain scores and the frequency of requiring rescue analgesia.

Research also examined the use of Indicam for Menstrual Cramps (Primary Dysmenorrhea), with studies focused strictly on the acute evaluation of pain over a single menstrual cycle. These acute studies are considered highly specific and contribute to the broader evidence landscape for short-term symptom patterns.


What is Still Uncertain About Indicam Research

The research on Indicam has several areas where the evidence remains incomplete or where certainty is limited. Long-term effects are not fully established, and there is limited information detailing sustained, multi-year outcomes, particularly in large, controlled settings. The evidence quality varies across studies, especially when comparing all the different ways the medicine can be administered (oral, topical, injectable).

Additionally, subgroup findings are uncertain for many groups beyond the core studied populations. Comparative evidence is often lacking for direct, head-to-head comparisons of all formulations and dosages against every other available treatment option. Research provides context but not individual predictions, and findings describe group patterns, not personal outcomes.

Key Studies & References

  1. Effect of a topical diclofenac solution for relieving symptoms of primary osteoarthritis of the knee: a randomized controlled trial (used for topical vs. oral comparison and general OA outcomes)

Frequently Asked Questions (FAQ)

Common questions about Indicam (FAQ)


Q: What is Indicam used for?

Indicam is officially indicated for the short-term treatment of moderate to severe acute pain in adults when treatment by intravenous or intramuscular injection is considered appropriate. This typically applies to situations like postoperative pain. According to regulatory documents, it is intended for use when non-opioid medications are not sufficient.


Q: Is Indicam a type of opioid medicine?

No, Indicam is not an opioid. It belongs to a class of medicines called Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Official product information indicates that it acts to reduce the production of substances in the body associated with pain and inflammation.


Q: How long can I be treated with Indicam?

Indicam is only intended for short-term use. Regulatory sources clearly state that the total duration of treatment, including the transition from injection to oral or rectal dosing, should not exceed 5 days. This limit is in place to minimize potential risks, such as gastrointestinal side effects.


Q: What should I do if I miss a dose of Indicam?

If a dose of Indicam is missed, the official product information states that taking a double dose to compensate for a missed one is not advised. The labeling directs patients to continue with the next scheduled dose as originally prescribed. It is important to maintain the short-term treatment plan.


Q: Can Indicam be used for chronic pain?

No, Indicam is not indicated for the management of chronic long-term pain. According to the official product information, it is strictly indicated only for the short-term management of acute moderate to severe pain. Long-term use is associated with a higher risk of serious adverse effects.


Q: Does Indicam cause drowsiness?

Studies and official information indicate that Indicam can cause some side effects that may affect your ability to drive or operate machinery. These may include drowsiness, dizziness, or vision problems. The official product information notes that if these effects occur, activities requiring mental alertness, like driving, should be avoided.


Q: Can I drink alcohol while taking Indicam?

The official product information includes a warning that drinking alcohol should be avoided or strictly limited during treatment with Indicam. Alcohol can increase the risk of side effects, particularly those affecting the stomach and intestines, such as gastrointestinal bleeding. The precaution is intended to apply throughout the short course of therapy.

How should Indicam be stored and disposed of?

Storage Requirements

Indicam (Diclofenac) must be stored strictly according to the conditions listed on the official regulatory label to preserve its stability.

Condition Requirement
Temperature Store at Controlled Room Temperature (20 C to 25 C). Do not store above 25 C or 30 C (varies by form/region).
Protection Protect from moisture and light. Protect from excessive heat.
Packaging Keep the medicine in a tightly closed or original container.
Child Safety Keep out of the reach and sight of children at all times.

Official Disposal Rules

Unused or expired Indicam must be disposed of properly. The product must not be flushed down a toilet or sink. The preferred method for disposal is returning the medicine to a community drug take-back program or utilizing a pharmacy mail-back envelope. If a take-back option is not available, the medicine should be mixed with an undesirable substance, sealed in a container, and placed in the household trash, following established regulatory guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Indicam found in:

A-Z Index: